Compare CPF & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPF | HELP |
|---|---|---|
| Founded | 1954 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 916.6M | 862.2M |
| IPO Year | 2011 | 2020 |
| Metric | CPF | HELP |
|---|---|---|
| Price | $37.87 | $10.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $41.75 | $41.40 |
| AVG Volume (30 Days) | 125.1K | ★ 1.3M |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ 45.18 | N/A |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $51,817,000.00 | N/A |
| Revenue This Year | $4.16 | N/A |
| Revenue Next Year | $3.45 | N/A |
| P/E Ratio | $23.92 | ★ N/A |
| Revenue Growth | ★ 33.81 | N/A |
| 52 Week Low | $28.10 | $3.76 |
| 52 Week High | $40.99 | $15.15 |
| Indicator | CPF | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 43.27 |
| Support Level | $36.91 | $9.97 |
| Resistance Level | $38.34 | $14.75 |
| Average True Range (ATR) | 0.65 | 0.93 |
| MACD | 0.29 | -0.05 |
| Stochastic Oscillator | 90.20 | 21.68 |
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.